News
Burrill & Company Announces Close of Burrill Brazil Fund I January 18, 2012 | Press Release
David Wetherell Joins Burrill & Company Venture Capital Group as Managing Director January 06, 2012 | Press Release
Global Financial Market Turmoil Overshadows Biotech Successes in 2011 January 03, 2012 | Press Release
See all News
Neos Therapeutics® is a privately owned drug delivery and full service contract manufacturing company serving prescription pharmaceutical and consumer healthcare markets.
Neos’ proprietary drug delivery technology platform is clinically proven. Our operating model is to develop prescription and OTC products working in partnership with healthcare companies. The Neos technology enables creation of innovative dosage forms, notably controlled release (CR) liquids and CR orally disintegrating tablets (ODTs).
Our expertise, technology and full service contract manufacturing spans the range of oral drug dosage forms from conventional tablets and capsules to the truly unique CR liquids and CR ODTs.
A dedicated R&D team working in our state-of-the-art, FDA-approved facility enables Neos to collaborate effectively from the initial stage of drug development through finished packaging for commercial sale. Throughout the entire process we strive to meet our partner’s needs and provide unique product offerings.

